Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Average Recommendation of “Hold” from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have earned an average rating of “Hold” from the six brokerages that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $16.57.

Several research firms have commented on YMAB. HC Wainwright boosted their price objective on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, March 6th. Canaccord Genuity Group increased their price objective on Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, March 4th. BMO Capital Markets lifted their target price on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a research note on Monday, March 4th. Finally, Wedbush reaffirmed an “outperform” rating and set a $18.00 target price (up previously from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th.

Insiders Place Their Bets

In related news, SVP Vignesh Rajah sold 1,711 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $16.53, for a total value of $28,282.83. Following the completion of the sale, the senior vice president now owns 33,889 shares of the company’s stock, valued at $560,185.17. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 21.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Trexquant Investment LP increased its stake in Y-mAbs Therapeutics by 417.5% during the third quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock worth $417,000 after acquiring an additional 61,785 shares during the last quarter. Acadian Asset Management LLC raised its holdings in Y-mAbs Therapeutics by 24.0% in the 3rd quarter. Acadian Asset Management LLC now owns 811,261 shares of the company’s stock valued at $4,420,000 after buying an additional 157,173 shares during the period. GSA Capital Partners LLP raised its holdings in Y-mAbs Therapeutics by 208.3% in the 3rd quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock valued at $748,000 after buying an additional 92,765 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Y-mAbs Therapeutics in the fourth quarter valued at about $34,000. Finally, Massachusetts Financial Services Co. MA boosted its stake in Y-mAbs Therapeutics by 258.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 82,131 shares of the company’s stock worth $448,000 after buying an additional 59,201 shares during the period. 70.85% of the stock is currently owned by institutional investors and hedge funds.

Y-mAbs Therapeutics Stock Performance

Shares of NASDAQ YMAB opened at $15.14 on Wednesday. The firm has a fifty day moving average of $15.64 and a 200 day moving average of $10.02. The firm has a market cap of $662.83 million, a PE ratio of -30.90 and a beta of 0.74. Y-mAbs Therapeutics has a one year low of $4.60 and a one year high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.17. The business had revenue of $23.36 million for the quarter, compared to analyst estimates of $21.72 million. Y-mAbs Therapeutics had a negative net margin of 25.26% and a negative return on equity of 20.72%. On average, equities analysts predict that Y-mAbs Therapeutics will post -0.43 EPS for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.